Literature DB >> 32034488

Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.

Niels W Schurink1,2, Lisa A Min1,2, Maaike Berbee2,3, Wouter van Elmpt2,3, Joost J M van Griethuysen1,2, Frans C H Bakers4, Sander Roberti5, Simon R van Kranen6, Max J Lahaye1, Monique Maas1, Geerard L Beets2,7, Regina G H Beets-Tan1,2, Doenja M J Lambregts8.   

Abstract

OBJECTIVES: To explore the value of multiparametric MRI combined with FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.
METHODS: Sixty-one locally advanced rectal cancer patients who underwent a baseline FDG-PET/CT and MRI (T2W + DWI) and received long-course neoadjuvant chemoradiotherapy were retrospectively analysed. Tumours were delineated on MRI and PET/CT from which the following quantitative parameters were calculated: T2W volume and entropy, ADC mean and entropy, CT density (mean-HU), SUV maximum and mean, metabolic tumour volume (MTV42%) and total lesion glycolysis (TLG). These features, together with sex, age, mrTN-stage ("baseline parameters") and the CRT-surgery interval were analysed using multivariable stepwise logistic regression. Outcome was a good (TRG 1-2) versus poor histopathological response. Performance (AUC) to predict response was compared for different combinations of baseline ± quantitative imaging parameters and performance in an 'independent' dataset was estimated using bootstrapped leave-one-out cross-validation (LOOCV).
RESULTS: The optimal multivariable prediction model consisted of a combination of baseline + quantitative imaging parameters and included mrT-stage (OR 0.004, p < 0.001), T2W-signal entropy (OR 7.81, p = 0.0079) and T2W volume (OR 1.028, p = 0.0389) as the selected predictors. AUC in the study dataset was 0.88 and 0.83 after LOOCV. No PET/CT features were selected as predictors.
CONCLUSIONS: A multivariable model incorporating mrT-stage and quantitative parameters from baseline MRI can aid in identifying well-responding patients before the start of treatment. Addition of FDG-PET/CT is not beneficial. KEY POINTS: • A multivariable model incorporating the mrT-stage and quantitative features derived from baseline MRI can aid in identifying well-responding patients before the start of neoadjuvant chemoradiotherapy. • mrT-stage was the strongest predictor in the model and was complemented by the tumour volume and signal entropy calculated from T2W-MRI. • Adding quantitative features derived from pre-treatment PET/CT or DWI did not contribute to the model's predictive performance.

Entities:  

Keywords:  Logistic models; Magnetic resonance imaging; Neoadjuvant therapy; Positron emission tomography computed tomography; Rectal neoplasms

Mesh:

Substances:

Year:  2020        PMID: 32034488     DOI: 10.1007/s00330-019-06638-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  49 in total

Review 1.  Value of (18)F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis.

Authors:  Anna Margherita Maffione; Maria Cristina Marzola; Carlo Capirci; Patrick M Colletti; Domenico Rubello
Journal:  AJR Am J Roentgenol       Date:  2015-06       Impact factor: 3.959

2.  Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging.

Authors:  Luís Curvo-Semedo; Doenja M J Lambregts; Monique Maas; Thomas Thywissen; Rana T Mehsen; Guido Lammering; Geerard L Beets; Filipe Caseiro-Alves; Regina G H Beets-Tan
Journal:  Radiology       Date:  2011-06-14       Impact factor: 11.105

3.  Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

Authors:  E Akgun; C Caliskan; O Bozbiyik; T Yoldas; M Sezak; S Ozkok; T Kose; B Karabulut; M Harman; O Ozutemiz
Journal:  Br J Surg       Date:  2018-08-29       Impact factor: 6.939

4.  Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance.

Authors:  Carlo N De Cecco; Balaji Ganeshan; Maria Ciolina; Marco Rengo; Felix G Meinel; Daniela Musio; Francesca De Felice; Nicola Raffetto; Vincenzo Tombolini; Andrea Laghi
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

Review 5.  The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.

Authors:  Ines Joye; Christophe M Deroose; Vincent Vandecaveye; Karin Haustermans
Journal:  Radiother Oncol       Date:  2014-11       Impact factor: 6.280

6.  Accuracy of Various Lymph Node Staging Criteria in Rectal Cancer with Magnetic Resonance Imaging.

Authors:  Jörn Gröne; Florian N Loch; Matthias Taupitz; C Schmidt; Martin E Kreis
Journal:  J Gastrointest Surg       Date:  2017-09-12       Impact factor: 3.452

7.  Semiquantitative Volumetry by Sequential PET/CT May Improve Prediction of Complete Response to Neoadjuvant Chemoradiation in Patients With Distal Rectal Cancer.

Authors:  Dalton A Dos Anjos; Rodrigo O Perez; Angelita Habr-Gama; Guilherme P São Julião; Bruna B Vailati; Laura M Fernandez; João B de Sousa; Carlos A Buchpiguel
Journal:  Dis Colon Rectum       Date:  2016-09       Impact factor: 4.585

8.  Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.

Authors:  Angelita Habr-Gama; Joaquim Gama-Rodrigues; Guilherme P São Julião; Igor Proscurshim; Charles Sabbagh; Patricio B Lynn; Rodrigo O Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

Review 9.  Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.

Authors:  Xiangjiao Meng; Zhaoqin Huang; Renben Wang; Jinming Yu
Journal:  Biosci Trends       Date:  2014-02       Impact factor: 2.400

10.  MRI texture analysis in predicting treatment response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Yankai Meng; Chongda Zhang; Shuangmei Zou; Xinming Zhao; Kai Xu; Hongmei Zhang; Chunwu Zhou
Journal:  Oncotarget       Date:  2017-12-22
View more
  3 in total

1.  Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Niels W Schurink; Simon R van Kranen; Maaike Berbee; Wouter van Elmpt; Frans C H Bakers; Sander Roberti; Joost J M van Griethuysen; Lisa A Min; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2021-02-10       Impact factor: 5.315

2.  MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer.

Authors:  Maxiaowei Song; Shuai Li; Hongzhi Wang; Ke Hu; Fengwei Wang; Huajing Teng; Zhi Wang; Jin Liu; Angela Y Jia; Yong Cai; Yongheng Li; Xianggao Zhu; Jianhao Geng; Yangzi Zhang; XiangBo Wan; Weihu Wang
Journal:  Br J Cancer       Date:  2022-04-02       Impact factor: 9.075

3.  Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid 18F-FDG PET/MRI: preliminary results of a rectal cancer cohort study.

Authors:  Shidong Hu; Xiaowei Xing; Jiajin Liu; Baixuan Xu; Xiaohui Du; Xi Liu; Jinhang Li; Wei Jin; Songyan Li; Yang Yan; Da Teng; Boyan Liu; Yufeng Wang
Journal:  Quant Imaging Med Surg       Date:  2022-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.